MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of “Hold” from Analysts

Posted by on Sep 11th, 2026

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) has earned an average recommendation of “Hold” from the seventeen brokerages that are covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $24.5714.

MLTX has been the topic of several recent analyst reports. HC Wainwright raised their target price on shares of MoonLake Immunotherapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Weiss Ratings raised shares of MoonLake Immunotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 21st. Leerink Partners upped their target price on MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 1st. Finally, BTIG Research reaffirmed a “buy” rating and issued a $30.00 target price on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 9th.

Read Our Latest Report on MLTX

Insider Activity

In other MoonLake Immunotherapeutics news, CEO Silva Santos sold 68,289 shares of MoonLake Immunotherapeutics stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $20.02, for a total value of $1,367,145.78. Following the transaction, the chief executive officer owned 2,774,893 shares in the company, valued at $55,553,357.86. The trade was a 2.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock in a transaction dated Tuesday, July 21st. The shares were sold at an average price of $20.02, for a total value of $1,001,000.00. Following the completion of the transaction, the insider owned 2,714,746 shares in the company, valued at approximately $54,349,214.92. This represents a 1.81% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 344,800 shares of company stock worth $6,820,071 over the last ninety days. 10.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in MLTX. Kestra Advisory Services LLC bought a new position in MoonLake Immunotherapeutics in the 4th quarter valued at approximately $26,000. Bank of America Corp DE lifted its stake in shares of MoonLake Immunotherapeutics by 64.7% in the 3rd quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock valued at $32,000 after acquiring an additional 1,781 shares during the last quarter. Allworth Financial LP boosted its holdings in shares of MoonLake Immunotherapeutics by 156.2% during the 2nd quarter. Allworth Financial LP now owns 1,714 shares of the company’s stock valued at $33,000 after acquiring an additional 1,045 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in shares of MoonLake Immunotherapeutics during the 2nd quarter valued at $39,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in MoonLake Immunotherapeutics by 115.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after acquiring an additional 3,166 shares during the last quarter. 93.85% of the stock is owned by institutional investors.

MoonLake Immunotherapeutics Stock Performance

MLTX opened at $13.18 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 12.56 and a current ratio of 12.56. MoonLake Immunotherapeutics has a 52-week low of $5.95 and a 52-week high of $62.75. The firm has a market cap of $1.12 billion, a P/E ratio of -3.43 and a beta of 1.04. The business’s fifty day moving average is $17.39 and its 200-day moving average is $17.78.

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.84) EPS for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.07. Sell-side analysts expect that MoonLake Immunotherapeutics will post -3.34 EPS for the current fiscal year.

MoonLake Immunotherapeutics Company Profile

(Get Free Report)

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Featured Articles

Analyst Recommendations for MoonLake Immunotherapeutics (NASDAQ:MLTX)

Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.